Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

28.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 28.47
Bid (Size) 27.00 (3)
Ask (Size) 45.26 (1)
Prev. Close 28.47
Today's Range 28.47 - 28.47
52wk Range 13.82 - 29.30
Shares Outstanding 90,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad 
From Myriad Genetics, Inc.
Via GlobeNewswire
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
+49.84%
+49.84%
1 Month
+0.74%
+0.74%
3 Month
+19.62%
+19.62%
6 Month
+28.01%
+28.01%
1 Year
+64.00%
+64.00%

More News

Read More
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Key Takeaways From Myriad Genetics Analyst Ratings
Via Benzinga
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Via Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Avantor Stock Earns 84 RS Rating
Via Investor's Business Daily
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Myriad Genetics Earns 2024 Great Place To Work® Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Via MarketBeat
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
From Myriad Genetics, Inc.
Via GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.